Number (%) of subjects | ||||
---|---|---|---|---|
Preferred term | NBMI 100 mg (n = 13) | NBMI 300 mg (n = 11) | Placebo (n = 12) | Total (n = 36) |
Number of subjects with any AE* | 6 (46.2%) | 5 (45.5%) | 8 (66.7%) | 19 (52.8%) |
Headache | 5 (38.5%) | 3 (27.3%) | 4 (33.3%) | 12 (33.3%) |
Abdominal pain upper | 1 (7.7%) | 1 (9.1%) | 2 (16.7%) | 4 (11.1%) |
Abdominal pain | 1 (9.1%) | 2 (16.7%) | 3 (8.3%) | |
Diarrhoea | 1 (7.7%) | 1 (8.3%) | 2 (5.6%) | |
Somnolence | 1 (7.7%) | 1 (8.3%) | 2 (5.6%) | |
Animal bite | 1 (9.1%) | 1 (2.8%) | ||
Arthralgia | 1 (8.3%) | 1 (2.8%) | ||
Back pain | 1 (8.3%) | 1 (2.8%) | ||
Ear pain | 1 (7.7%) | 1 (2.8%) | ||
Gastroenteritis | 1 (7.7%) | 1 (2.8%) | ||
Ingrowing nail | 1 (7.7%) | 1 (2.8%) | ||
Insomnia | 1 (8.3%) | 1 (2.8%) | ||
Lip dry | 1 (8.3%) | 1 (2.8%) | ||
Oropharyngeal pain | 1 (8.3%) | 1 (2.8%) | ||
Vertigo | 1 (8.3%) | 1 (2.8%) |